21 results about "Platelet inhibition" patented technology

Methods of inhibiting platelet activation and aggregation using peptide vaccines having binding specificity for the α subunit of the (Na++K+)-ATPase are provided, along with methods for inhibiting or preventing or treating thrombosis without causing bleeding.

The invention provides a composition for improving the thrombolysis capacity of a human body, a preparation method and application thereof.The composition is prepared from, by weight, 5-30 parts of earthworm protein, 30-120 parts of hippophae rhamnoides total flavone extract, 50-150 parts of silymarin extract, 20-80 parts of maltodextrin and 15-60 parts of pregelatinized starch, the earthworm protein activates a fibrinolytic system to promote t-PA to release and dissolve thrombus, and the hippophae rhamnoides total flavone extract activates the fibrinolytic system to promote t-PA to release and dissolve thrombus; the hippophae rhamnoides total flavonoids regulate the ratio of PGI2 / TXA2 to inhibit platelet aggregation and reduce blood fat, the silymarin protects the liver function to enhance LDL-C metabolism clearing, the hippophae rhamnoides total flavonoids, the silymarin and the hippophae rhamnoides total flavonoids cooperate to form a thrombolysis-antithrombosis-metabolism regulation three-dimensional intervention system, a whole-course low-temperature mixing direct tabletting process is adopted

The objective is to provide a method that suppresses the formation of pseudopods of platelets during the preparation of PRP, thereby preventing the formation of aggregates. [Solution] The method for producing platelet-rich plasma (PRP) according to the present invention is characterized by adding a local anesthetic to the blood when producing PRP.

The application relates to the technical field of coating surface preparation, in particular to an anticoagulant coating based on a novel tick-derived anticoagulant protein Qinghaienin and a preparation method thereof. 167‑192 Wherein the amino acid sequence of the functional peptide segment is shown in SEQ ID NO. 2. The anticoagulant coating is prepared by using a polydopamine coating as a base layer, and then covalently grafting the anticoagulant protein Qinghaienin or the functional peptide segment Qinghaienin 167‑192 which can inhibit the activation of the FXII factor is covalently grafted through an amide bond to the surface of a medical polymer material, and a novel anticoagulant coating is successfully constructed. Compared with unmodified medical polymer materials, the modified coating can significantly enhance the hydrophilicity of the material, inhibit platelet adhesion and activation, effectively prolong the blood clotting time in vitro, and exhibit excellent anticoagulant performance.

This invention relates to the field of biomedicine, specifically to the application of banana fruit extract in the preparation of anticoagulant or antithrombotic drugs. The banana fruit extract provided by this invention contains flavonoids, polyphenols, polysaccharides, hydroxyanthraquinones, triterpenoids, and other components. Flavonoids and polyphenols have been widely proven to have anti-inflammatory and antioxidant effects, which can synergistically enhance the anticoagulant effect. The high potassium content of banana fruit can indirectly improve vascular function by regulating sodium-potassium balance. The banana fruit extract provided by this invention can inhibit platelet production or promote platelet metabolism, prolong clotting time, and inhibit platelet aggregation. Its natural plant components interfere with platelet aggregation by inhibiting the production of thromboxane A2, achieving anticoagulant and antithrombotic effects. The mechanism of action of banana fruit extract differs from traditional anticoagulants such as heparin, reducing the risk of bleeding. Its natural component characteristics provide a direction for the development of novel plant-derived anticoagulant drugs.

The invention discloses application of a compound in preparation of a medicine for treating or relieving ADPGK activation related concurrent diseases in chronic kidney diseases. The compound is found to be capable of effectively inhibiting the activity of ADPGK through computer virtual screening in combination with an in-vitro platelet activation experiment. In CKD patient and mouse models, the Z809269780 significantly reduces the glycolysis flux of platelets, lactic acid generation and RHOA lactylation level, thereby inhibiting the excessive activation and high reactivity of the platelets, and effectively relieving thrombosis events (such as platelet aggregation, adhesion, blood clot retraction and arterial thrombosis). Animal experiments show that intraperitoneal injection of the Z809269780 (10 mg / kg) has a good antithrombotic effect, and the Z809269780 does not show obvious toxicity under the dosage of 20 mg / kg. The invention provides a safe and effective novel targeted treatment strategy for preventing thrombotic complications of CKD patients.

The present application relates to the field of biomaterials, and particularly relates to a biomimetic biological valve. The biomimetic biological valve is obtained by wrapping a non-crosslinked biological basement membrane around a crosslinked extracellular matrix material to form a sandwich structure. The basement membrane cooperates with the crosslinked extracellular matrix material, fully plays the excellent regenerative repair performance and the characteristics of being rich in bioactive factors of the basement membrane, effectively promotes the growth and adhesion of endothelial cells on the surface of the material, and constructs a tissue structure similar to the natural valve leaflet. The biomimetic biological valve exhibits excellent anti-calcification performance and excellent dynamic mechanical stability and compliance, significantly inhibits the abnormal adhesion of platelets and blood cells, greatly improves the recovery and reconstruction efficiency of the valve function, and can maintain the structural integrity in repeated contraction-expansion cycles, providing an ideal solution for long-term stable application in a physiological environment.

This invention belongs to the field of traditional Chinese medicine (TCM) technology, specifically relating to a TCM composition with detoxifying and uterus-warming effects and its application in the preparation of external products. The medicinal component of this external TCM product is composed of fenugreek, amethyst, rose, pomegranate seed, centella asiatica, long pepper, five-finger peach, lycopodium, litchi seed, and achyranthes bidentata. Animal experiments show that this product can significantly reduce the number of writhing movements in animals with cold-induced blood stasis type dysmenorrhea, lower COX-2 and PGE2 levels in the uterus, and improve peritoneal inflammation, demonstrating good detoxifying, blood stasis-removing, menstruation-regulating, and pain-relieving effects. Regarding blood rheology, it exhibits the effects of inhibiting platelet aggregation, dilating blood vessels, reducing blood viscosity, and balancing TXA2 and PGI2 levels, reflecting its effects of warming the kidneys and uterus, and strengthening the body's foundation. In summary, the TCM composition of this invention and its prepared external product can warm the kidneys and uterus, promote diuresis and eliminate turbidity, providing a novel TCM external application solution for the clinical treatment of cold-induced blood stasis type dysmenorrhea.

The present disclosure relates to inhibition of platelet absorption. Cardiovascular grafts with highly reduced thrombosis are provided. The cardiovascular graft is an electrospun nonwoven web produced from a supramolecular polymer of large diameter fibers. The cardiovascular graft can be implanted in a human body as a vascular graft to allow blood vessel bypass / reconstruction, or repeated venous access for dialysis treatment, as well as other small diameter vascular disorders.

The present application provides a Bifidobacterium breve. The strain has high yield of acetoin and has milk clotting function. The present application provides a fermenting agent comprising the Bifidobacterium breve. The preparation method of the fermenting agent is also provided. The present application also provides a fermented ovine colostrum, which contains a plurality of functional polypeptides. The present application also provides a preparation method of the fermented ovine colostrum. The method can simultaneously ensure high retention rate of nutrients in the ovine colostrum. The present application also provides a polypeptide. The polypeptide can inhibit angiotensin converting enzyme activity, improve vascular endothelial function or inhibit platelet aggregation, and has cardiovascular protection ability. The present application also provides a polypeptide composition. The present application also provides application of the Bifidobacterium breve, the polypeptide and / or the fermented ovine colostrum in the field of food or medicine for helping to enhance immunity.

Multivalent anti-platelet glycoprotein I(b)alpha antibodies can cause severe side effects. The present disclosure provides humanized antibodies specifically recognizing glycoprotein I(b)alpha and lacking a Fc portion, therefore Bleeding Time do not interact with Fc receptor. The humanized antibodies are capable of preventing platelet activation and aggregation, and reducing thrombus size / growth and prevent vessel occlusion. They can be also very useful to decrease platelet-tumor cell interaction and decrease tumor metastasis. At therapeutic doses, the humanized antibodies lack the ability to induce platelet activation, induce thrombocytopenia; and / or prolong bleeding time.

This invention provides a multifunctional electrospun material and its application, as well as an artificial blood vessel and its preparation method. The electrospun material includes an electrospun material substrate and deferoxamine. This electrospun material possesses anti-inflammatory, antioxidant, antibacterial, and anticoagulant functions. When applied to the preparation of artificial blood vessels, it can improve the regenerative capacity of blood vessels, especially by protecting vascular cells through inhibiting inflammation and hyperglycemia-induced oxidative stress in diabetic and elderly patients, thereby promoting angiogenesis. The loaded deferoxamine can achieve long-term, slow release according to the environment of the transplantation site. The released deferoxamine can prevent acute thrombosis by inhibiting platelet adhesion and activation, and can also protect the microenvironment of the transplantation site by resisting oxidative stress and inflammation levels, promoting cell infiltration and regeneration, and protecting regenerated cells.

The application discloses an enhanced anti-coagulation and anti-bacterial hemodialysis hollow fiber membrane and a preparation method thereof, and belongs to the technical field of medical membrane materials. The acid activation-polydopamine coating-sulfonated grafting modification of halloysite nanotubes is carried out in the application, so that the surface sulfonic acid group density of the halloysite nanotubes reaches 0.8-2.1 mmol / g, and the Zeta potential is less than or equal to-30 mV. The modified halloysite is dispersed in a polar aprotic solvent in advance, is incorporated into a polymer matrix after ultrasonic treatment, is filtered through a sintering filter element with a diameter of less than or equal to 5 mu m, is defoamed, is spun by using a dry spraying-wet spinning method, and is prepared into a finished product through coagulation, rinsing and drying. The application constructs a heparin-like negative charge layer, so that the activated partial thromboplastin time (APTT) is greater than or equal to 55 s, platelet adhesion and protein adsorption are significantly inhibited, and the application has a broad-spectrum antibacterial performance. The rigid halloysite induces the formation of through channels, so that the pain point that a high-flux membrane is easy to damage red blood cells is solved, the process is stable, and the application is suitable for industrial production.

The invention relates to the field of molecular biology and biological medicine, and particularly discloses an antithrombotic effect of Meteorin protein or gene. Experiments prove that after Meteorin protein is incubated, the platelet aggregation reaction can be remarkably inhibited, the platelet spreading area can be reduced, blood clot contraction can be delayed, and meanwhile ATP release and alpha particle release of platelets and activation of surface integrin alpha IIb beta 3 can be inhibited. In a whole thrombus experiment, the Meteorin protein can effectively inhibit the formation of arterial thrombosis. The Meteorin protein is a human endogenous protein, so that the Meteorin protein has relatively small side effects, has relatively high safety as a potential drug, and has a good industrialization prospect.

The invention provides a rare-earth-based anticoagulant coating for a PVC pipeline and a preparation method thereof, and the preparation method comprises the following steps: uniformly mixing a rare-earth-based complex with chitosan, citric acid, glycerol and deionized water, heating to obtain a colloidal mixed system, smearing the mixed system on the inner wall of the PVC pipeline, and drying to obtain the rare-earth-based anticoagulant coating for the PVC pipeline. And cooling and curing to obtain the rare earth-based anticoagulant coating. According to the rare-earth-based anticoagulant coating for the PVC pipeline, quaternary ammonium groups (N + (CH3) 3) of chitosan quaternary ammonium salt and a coordination hydration layer of rare earth ions have a synergistic effect, so that platelet adhesion is remarkably inhibited; the quaternary ammonium group is positively charged and can compete for adsorption with electronegative glycoprotein (GP Ib / IX / V) on the surface of the blood platelet through electrostatic interaction, so that the initial adhesion of the blood platelet is reduced.

The invention discloses an anti-Xa factor detection kit, and relates to the technical field of in vitro diagnosis. The anti-Xa factor detection kit comprises a reagent R1 and a reagent R2, the reagent R1 mainly comprises a first buffer solution, inorganic salt, a stabilizer, FXa, a first preservative, vanadate, an inhibitor and alkoxy polyethylene hydroxyl ethanol; the inhibitor is used for inhibiting the blood coagulation effect of the platelet factor 4; the reagent R2 comprises a second buffer solution, an FXa chromophoric substrate, a sugar alcohol substance and a second preservative. The anti-Xa factor detection kit provided by the invention is strong in anti-interference capability and accurate in detection, can realize pretreatment-free direct detection on chyle samples, can resist interference of interferents such as bilirubin and hemoglobin, and can meet the requirements of clinical complex sample detection.

The present invention relates to: a pharmaceutical composition for preventing or treating thrombotic diseases, the pharmaceutical composition comprising a compound of chemical formula 1 or an acceptable salt thereof; and a health functional food composition or cosmetic composition which is for improving blood circulation and comprises same Specifically, in the present invention, the compound of chemical formula 1 was found to simultaneously inhibit NOX1 and NOX2 and thus be highly effective in inhibiting platelet aggregation and thrombus formation.

The invention relates to the technical field of medicines, in particular to application of uric acid in preparation of a medicine for treating liver injury and a medicine for inhibiting platelets during liver injury. The invention relates to an application of uric acid in the aspects of treating liver injury and inhibiting platelet activation, which indicates that uric acid (especially exogenous uric acid) can be used for preparing the medicines for treating liver injury and platelet activation, and provides technical enlightenment for preparing the medicines for treating liver injury and liver cirrhosis hypercoagulable state. The invention discloses that exogenous uric acid has a treatment effect on acute liver injury induced by thioacetamide (TAA). The exogenous uric acid has a treatment effect on chronic liver injury caused by cholestasis. The mechanism is related to reduction of oxidative stress and inflammatory response and further reduction of cell senescence. The condition of a liver cirrhosis patient is related to the platelet activation state, exogenous uric acid inhibits TAA and platelet activation in a common bile duct ligation (BDL) rat model, and it is prompted that the liver disease and the liver cirrhosis hypercoagulable state can be treated.

The application belongs to the technical field of biological medicine, and particularly relates to a Buthus martensii Karsch (Buthus martensii Karsch) oligopeptide and application thereof in preparation of anti-platelet and anti-thrombus drugs or compositions. Buthus martensii The application discloses an anti-platelet oligopeptide discovered by combining an active-oriented separation with computer virtual screening based on a Karsch transcriptome database. The oligopeptide can not only inhibit platelet aggregation, but also effectively inhibit platelet adhesion and expansion. In a thrombus model experiment in vivo, the Buthus martensii Karsch oligopeptide discovered by the application can well inhibit FeCl3-induced carotid artery thrombosis of a mouse. Meanwhile, it is found that the Buthus martensii Karsch oligopeptide does not have obvious bleeding tendency. In conclusion, the Buthus martensii Karsch oligopeptide can be used as an anti-platelet aggregation and anti-thrombus drug to play a certain positive role in the prevention and treatment of thrombotic diseases.

According to the pyrolytic carbon with the super-hydrophobic surface, firstly, various micro-nano structures are obtained through a laser etching technology, then copper ions are loaded through dopamine chelating, then surface modification is conducted through low-surface-energy substances, and the super-hydrophobic surface containing a copper ion coating is obtained. According to the obtained pyrolytic carbon mechanical valve super-hydrophobic surface, the surface static water contact angle is larger than 150 degrees, the rolling angle is smaller than 10 degrees, when the pyrolytic carbon mechanical valve super-hydrophobic surface makes contact with blood, a nitrosoglutathione donor in the blood is catalyzed by Cu < 2 + > to release NO gas, a gas film which is automatically dissipated and has the anticoagulation function on the super-hydrophobic surface is repaired, the dynamic stability of the gas film is maintained, and the anti-coagulation effect is achieved. NO can inhibit adhesion and activation of platelets, so that the pyrolytic carbon super-hydrophobic surface has a long-acting anticoagulation function, and the pyrolytic carbon super-hydrophobic surface can be applied to anticoagulation modification of the surface of the mechanical valve.